LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

40.26 3.79

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

43.48

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+4.02% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.9B 6.1B
Vorheriger Eröffnungskurs	36.47
Vorheriger Schlusskurs	40.26

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Dez. 2025, 23:48 UTC

Wichtige Markttreiber

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8. Dez. 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8. Dez. 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8. Dez. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Dez. 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8. Dez. 2025, 23:09 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8. Dez. 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8. Dez. 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8. Dez. 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Dez. 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8. Dez. 2025, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8. Dez. 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8. Dez. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8. Dez. 2025, 21:12 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. Dez. 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8. Dez. 2025, 20:38 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8. Dez. 2025, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8. Dez. 2025, 20:18 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8. Dez. 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8. Dez. 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8. Dez. 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Dez. 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8. Dez. 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

4.02% Vorteil

12-Monats-Prognose

Durchschnitt 40.33 USD 4.02%

Hoch 53 USD

Tief 20 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.